N6022 exhibited a sustained duration of action in OVA-sensitized mice. OVA-sensitized mice were treated with a single i.v. dose of N6022 administered 1 h to 48 h prior to MCh challenge. PBS vehicle was given as a single i.v. dose 24 h prior to MCh challenge. IpBr + Alb was administered as inhaled doses at 48 h, 24 h, and 1 h prior to MCh as a positive control for the model. Dosing at 24 h prior to MCh challenge occurred one hour prior to the last OVA challenge on study day 22. Penh was measured at baseline and after challenge with saline followed by increasing doses of MCh aerosol. BALF eosinophils were quantified via light microscopy. Plasma MMP-9 was measured via ELISA. N6022 attenuated Penh (A), BALF eosinophils (B), and plasma MMP-9 (C) in OVA-sensitized mice starting as early as one hour with effects sustained for up to 48 h. Bars are the means ± SEM of 10 mice per group for (A) and (B), and 5 mice per group for (C). *p < 0.05 for treatment vs. vehicle, One-way ANOVA, Dunnett’s.